Thoracotomy vs Thoracoscopy for Metastatic Osteosarcoma
Trial Summary
What is the purpose of this trial?
This phase III trial compares the effect of open thoracic surgery (thoracotomy) to thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastases). Open thoracic surgery is a type of surgery done through a single larger incision (like a large cut) that goes between the ribs, opens up the chest, and removes the cancer. Thoracoscopy is a type of chest surgery where the doctor makes several small incisions and uses a small camera to help with removing the cancer. This trial is being done evaluate the two different surgery methods for patients with osteosarcoma that has spread to the lung to find out which is better.
Will I have to stop taking my current medications?
The trial protocol does not specify whether you need to stop taking your current medications. However, newly diagnosed patients must have completed or be receiving standard systemic therapy for osteosarcoma, so it's possible you may need to continue certain treatments.
What data supports the effectiveness of the treatment Thoracoscopy, Video-Assisted Thoracoscopic Surgery, VATS, Minimally Invasive Thoracic Surgery, Thoracotomy, Open Thoracic Surgery for metastatic osteosarcoma?
Research shows that both thoracotomy (open surgery) and thoracoscopy (minimally invasive surgery) can be used to remove lung metastases in osteosarcoma patients, with similar survival outcomes. Thoracoscopy may have better perioperative results, making it a suitable alternative to open surgery for some patients.12345
Is thoracoscopy (VATS) generally safe compared to thoracotomy?
Video-assisted thoracic surgery (VATS) is considered a safe and minimally invasive option compared to open thoracotomy, with studies suggesting it can be safely performed for conditions like lung cancer and pulmonary metastases. However, there are concerns about the need for emergency conversion to open thoracotomy during surgery, which could lead to complications.12678
How does the treatment of thoracotomy vs thoracoscopy for metastatic osteosarcoma differ from other treatments?
Thoracotomy and thoracoscopy are surgical treatments for removing lung metastases in osteosarcoma patients. Thoracotomy allows surgeons to feel for nodules that might not show up on scans, while thoracoscopy is less invasive and uses a camera to guide the surgery. Both approaches aim to remove all visible tumors, but there is no clear evidence that one method leads to better survival outcomes than the other.12349
Research Team
John J Doski
Principal Investigator
Children's Oncology Group
Eligibility Criteria
This trial is for patients under 50 with osteosarcoma that has spread to the lungs. They must have fewer than four small lung nodules, each no larger than 3 cm, and be on or have completed a specific chemotherapy regimen (MAP). Patients can't join if they've had previous lung surgery for metastasis, have an unresectable primary tumor, pleural or mediastinal lesions, pleural effusion, or central pulmonary lesions requiring lobectomy.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Patients undergo either open thoracic surgery (thoracotomy) or thoracoscopy (video-assisted thoracoscopic surgery or VATS) to treat pulmonary metastases.
Follow-up
Participants are monitored for safety and effectiveness after treatment, with follow-up visits at 7-14 days, 4-6 weeks, and 3 months post-surgery, then every 3 months for up to 2 years.
Treatment Details
Interventions
- Thoracoscopy (Procedure)
- Thoracotomy (Procedure)
Thoracoscopy is already approved in Canada, Japan for the following indications:
- Pulmonary metastases
- Lung cancer
- Pleural effusion
- Pneumothorax
- Empyema
- Pulmonary metastases
- Lung cancer
- Pleural effusion
- Pneumothorax
- Empyema
Find a Clinic Near You
Who Is Running the Clinical Trial?
Children's Oncology Group
Lead Sponsor
National Cancer Institute (NCI)
Collaborator